Navigation Links
Novel Product for the Prevention of Post-Surgical Adhesion Formation Completes Phase I Clinical Study
Date:7/14/2009

GOTHENBORG, Sweden, July 14 /PRNewswire/ -- PharmaSurgics AB. successfully completes Phase I clinical study showing their novel candidate drug PXL01 is safe and well tolerated. Initially developed to prevent post-surgical adhesion formation following hand surgery the product combines the pharmacological effect of PXL01 with the physical barrier effect of the vehicle, and has the potential to be the first anti-adhesion drug on the market. 'These results provide the foundation for proceeding to the next phase, proof of concept study in patients,' said Fredrik Sjovall, CEO of PharmaSurgics, adding 'the proof of concept study in patients of flexor tendon repair surgery is scheduled to start in December 2009.'

Post-surgical adhesions are bands of scar tissue connecting anatomic sites in the body that should not normally be connected. These develop after almost every type of surgery and cause symptoms such as restricted joint mobility, chronic pain, intestinal obstruction and re-operative complications. Following flexor tendon repair surgery post-surgical adhesions lead to decreased strength and function of the affected joints, extensive post-operative physiotherapy and extended periods of sick leave.

About PharmaSurgics

PharmaSurgics in Sweden AB is a Gothenburg based biotech company that develops and commercializes a novel treatment for preventing harmful scarring and promoting wound healing after surgery. PharmaSurgics product concept is based on proprietary synthetic peptides which have strong anti-inflammatory and anti-infectious properties. The company was founded in 2005, based on extensive research by Dr. Inger Mattsby- Baltzer and Professor Kjell Olmarker at Sahlgrenska University Hospital, Gothenborg, Sweden. PharmaSurgics is a Karolinska Development portfolio company.

    For further information please contact
    Fredrik Sjovall, CEO of PharmaSurgics
    Ph: +46-31-762-2
'/>"/>
SOURCE PharmaSurgics AB
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. EMcision Announces 510(k) Clearance of the Habib EndoHPB, its Novel Bipolar RF Device for the Palliation of Biliary and Pancreatic Tumours
2. Novel gene found for dilated cardiomyopathy
3. Novel drug discovery tool could identify promising new therapies for Parkinsons disease
4. Novel method predicts impact of a covert anthrax release
5. Microbix Files First Patent Applications On Novel Technology Platform For Large Semen Sexing Market
6. Novel handheld device detects anthrax with outstanding accuracy and reliability
7. Funxional Successfully Completes Initial Clinical Trial of FX125L, an Anti-Inflammatory Drug With a Novel Mechanism of Action
8. Palkion Selects Novel Oral Development Candidate for the Treatment of Anemia
9. Clavis Pharma Raises NOK 129 Million (USD 20 Million) in a Private Placement to Fund Further Development of its Pipeline of Novel Anticancer Drug Candidates
10. Glenmarks Novel Molecule for Diabetes, Melogliptin to Enter Phase III Trials
11. Allied Minds Establishes New Company to Commercialize Novel UC Irvine Tinnitus Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... , April 30, 2015 Oxford Finance ... debt to life sciences and healthcare services companies, today ... term loan agreement with Celula, Inc., a diagnostic testing ... diseases, enabling better patient care and improved outcomes.  Proceeds ... development and expand the commercialization of its products in ...
(Date:4/30/2015)... , April 30, 2015  Asterias Biotherapeutics, Inc. ... emerging field of regenerative medicine, today announced that it ... Thursday, May 7, 2015 after the close of the ... call and webcast on Thursday, May 7, 2015 at ... the results and recent corporate developments. For ...
(Date:4/30/2015)... SureClinical, a leader in cloud-based health ... joined SureClinical’s executive team as Chief Financial Officer. ... executive with over 25 years in leadership roles ranging ... Ms. Morris joins SureClinical from Marrone Bio Innovations (MBI), ... of MBI from its founding in 2006 until 2011, ...
(Date:4/29/2015)... GUELPH, ON , April 29, 2015 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ... twelve-month periods ended December 31, 2014. Biorem,s complete fiscal 2014 year-end financial ... FINANCIAL HIGHLIGHTS: 2014 , 2013 , 2014 ... 10,683 , 19,596 Gross profit 1,326 , ... 1,191 , 1,493 , 3,377 , ...
Breaking Biology Technology:Oxford Finance Provides $10 Million Debt Financing to Celula 2Asterias Biotherapeutics to Report First Quarter Results on May 7, 2015 2Asterias Biotherapeutics to Report First Quarter Results on May 7, 2015 3Julie I. Morris Joins SureClinical as Chief Financial Officer 2Biorem Reports Results for Fourth Quarter 2014 and Year Ended December 31, 2014 2Biorem Reports Results for Fourth Quarter 2014 and Year Ended December 31, 2014 3Biorem Reports Results for Fourth Quarter 2014 and Year Ended December 31, 2014 4
... Study Finds Use of the Internet Now Dominates Quantitative Research ... ... out of five market research,studies -- 60 percent of those fielded in ... 2007 Medefield Pharmaceutical,Market Research Trends Study., The report, released today, indicates ...
... Year - Only Nasal Powder Bird ... - Patient-Friendly (No Needles); No Preservatives - Stable at Room Temperature For 3 ... ... Carrington,Laboratories, Inc. (OTC Bulletin Board: CARN) today announced that its,wholly-owned subsidiary DelSite Biotechnologies, ...
... More Than 180,000 Patient Visits Each Year, East Coast,s ... Empower ... Control Over Medical Care, CEDAR KNOLLS, N.J., Feb. ... company specializing in,portable electronic medical records management solutions, today ...
Cached Biology Technology:Technology Transforms Market Research in Pharmaceutical Industry 2Technology Transforms Market Research in Pharmaceutical Industry 3Carrington Subsidiary DelSite Starts Making Test Batches of First Bird Flu Vaccine Offering Needle-free Self-Administration 2Carrington Subsidiary DelSite Starts Making Test Batches of First Bird Flu Vaccine Offering Needle-free Self-Administration 3Carrington Subsidiary DelSite Starts Making Test Batches of First Bird Flu Vaccine Offering Needle-free Self-Administration 4Hayes Clinical Labs to Market MedeFile's Proprietary Electronic Medical Record Management Solution to Patients 2Hayes Clinical Labs to Market MedeFile's Proprietary Electronic Medical Record Management Solution to Patients 3Hayes Clinical Labs to Market MedeFile's Proprietary Electronic Medical Record Management Solution to Patients 4
(Date:3/30/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/lc9bnl/global_gesture ... Gesture Recognition Market in Automotive Sector 2014-2018" report ... Global Gesture Recognition market in Automotive Sector to grow ... Gesture recognition is the ability of a ... an individual. Gesture recognition technology can be 2D-based or ...
(Date:3/24/2015)... DUBLIN , Mar. 24, 2015 Research and ... addition of the "Global Iris Recognition Market 2015-2019" ... forecast the Global Iris Recognition market to grow at ... This report covers the present scenario and ... for the period 2015-2019. To calculate the market size, ...
(Date:3/24/2015)... WASHINGTON , March 24, 2015   NexID ... applications with critical security-authentication needs, today announced the beginning ... fake-finger-detection (FFD) solution. The company, based in ... announcement at the three-day Connect:ID Expo, which began here ... NexID said version 2.0 of its SDK boosts ...
Breaking Biology News(10 mins):Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2
... (Jan. 25, 2008) The American Society for Neural ... 1-3, 2008 at the Sheraton Sand Key Resort in Clearwater, ... 2008. Abstracts may be submitted electronically at www.asntr.org ... same Web site. Celebrating its 15th anniversary in 2008, the ...
... wires may hold the answer to making solar cells ... Department of Engineering Physics at McMaster University, Cleanfield Energy ... a partnership to pursue the commercialization of nanowire technology ... type of nanowire technology developed at McMaster is able ...
... Determined to revive the grossly depleted soils of ... poverty and hunger, the Alliance for a Green Revolution ... program to restore the fertility of Africas soils. ... soils where rapid nutrient loss is sapping the ability ...
Cached Biology News:ASNTR 15th anniversary meeting to be held May 1-3 in Florida 2Nanowires hold promise for more affordable solar cells 2Alliance for a Green Revolution in Africa commits 180M to revive farmers' depleted soils 2Alliance for a Green Revolution in Africa commits 180M to revive farmers' depleted soils 3Alliance for a Green Revolution in Africa commits 180M to revive farmers' depleted soils 4
... Zyagen tissue microarrays are derived from frozen ... rigorous quality control procedures to ensure the ... manually assembled in one block, sectioned at ... coated slides. Sections are large (3-5mm in ...
... Zyagen tissue microarrays are derived from frozen ... rigorous quality control procedures to ensure the ... manually assembled in one block, sectioned at ... coated slides. Sections are large (3-5mm in ...
... Engine Opticon real-time PCR detection system uses ... excitation (450-495 nm) and a photomultiplier tube ... system is built on an DNA Engine ... gradient feature. This item includes the thermal ...
... for Optimal Microdissection , CapSure HS and ... and rapid extraction of populations of pure ... with Laser Capture Microdissection., Ensure the ... Analysis , All CapSure LCM Caps have ...
Biology Products: